⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8849626 | 0.62 | CYP1A2 (0.33) | — | |
| SCHEMBL25283850 | 0.62 | TNFRSF1A (0.35) | — | |
| SCHEMBL4438037 | 0.61 | ALDH1A1 (0.44) | — | |
| SCHEMBL27814680 | 0.61 | ALDH1A1 (0.33) | — | |
| SCHEMBL6112114 | 0.59 | DRD2 (0.40) | — | |
| SCHEMBL7994314 | 0.59 | CYP1A2 (0.34) | — | |
| SCHEMBL5502106 | 0.59 | GPR3 (0.46) | — | |
| SCHEMBL8695508 | 0.59 | CYP1A2 (0.39) | — | |
| SCHEMBL12143388 | 0.58 | TPMT (0.37) | — | |
| SCHEMBL2368966 | 0.58 | PREP (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |